What is the price and reimbursement ratio of Letermovir after medical insurance reimbursement?

Letermovir (Letermovir) is an antiviral drug mainly used to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplantation (HSCT). It specifically inhibits the CMV DNA terminase complex, thereby preventing viral replication and reducing the risk of infection in transplant patients. Clinical data show that letermovir is highly effective in preventing CMV infection in high-risk transplant patients. It is a commonly used antiviral preventive drug after hematopoietic stem cell transplantation.

In the Chinese market, letermovir has been officially launched, providing two dosage forms: tablets and injections. Tablet specifications are usually 240mg/ tablets, and injections are 240mg/ bottles. Both dosage forms have been included in the national medical insurance catalog. After being included in medical insurance, patients can reduce their medication burden according to the medical insurance reimbursement ratio, but the specific reimbursement amount will vary depending on regional medical insurance policies and hospital implementation standards. Overall, medical insurance reimbursement can significantly reduce patients’ out-of-pocket expenditures.

In terms of price, a box of domestic tablets costs tens of thousands of yuan, while a box of injections costs about five to six hundred yuan. The specific price is based on the latest real-time selling price in the pharmacy. After reimbursement by medical insurance, the actual amount paid by patients for tablets and injections will drop significantly. For example, if the medical insurance reimbursement ratio is around 70%, the out-of-pocket amount for tablets may drop to around three to four thousand yuan, while for injections it may drop to around two to three hundred yuan. This makes it more financially feasible for high-risk transplant patients to receive long-term preventive therapy.

In overseas markets, there are still some generic drugs, such as tablets produced by Lucius in Laos, which sell for about 2,000 yuan per box. Although the price is lower, there are certain differences in quality, stability and legality. If patients consider importing generic drugs, they need to carefully evaluate supply channels and drug sources, and use them under the guidance of professional doctors to ensure efficacy and safety. Overall, letermovir, which is covered by domestic medical insurance, provides patients with a reliable and accessible antiviral prevention option while also reducing the economic burden.

Reference materials:https://www.mayoclinic.org/drugs-supplements/letermovir-oral-route/description/drg-20406647